Key Takeaways
- Dr. Sharon Walmsley, who treated one of Toronto’s first AIDS patients in 1983, announced that a longtime patient may become the first Canadian cured of HIV.
- The patient received a stem‑cell transplant in 2021 for aggressive Burkitt lymphoma, using a donor with two copies of the CCR5‑Δ32 mutation that confers natural HIV resistance.
- After stopping antiretroviral therapy, the patient has maintained undetectable HIV for more than 10 months; if he remains HIV‑negative for 20 months post‑treatment, he will be classified as cured.
- Only ten people worldwide have achieved HIV cure via stem‑cell transplantation, all of whom underwent the procedure as a last‑resort cancer therapy.
- Stem‑cell transplants are risky, expensive, and infeasible for the majority of the 41 million people living with HIV, especially in low‑resource settings.
- The case provides valuable insights into HIV reservoirs and the role of graft‑versus‑host disease, informing future research toward broadly accessible cures.
- Dr. Walmsley emphasizes that while bone‑marrow transplant is not a universal solution, it illuminates pathways needed to develop safer, scalable HIV‑eradication strategies.
A Lifetime of Witnessing HIV’s Evolution
Dr. Sharon Walmsley began her career in 1983 as a medical intern confronting Toronto’s earliest AIDS patients, a time when HIV had no name, treatment, or hope. Decades later, she stood at a Winnipeg conference to announce that one of her longtime patients might become the first Canadian cured of the virus. Her journey mirrors the transformation of HIV from a swiftly fatal illness to a manageable chronic condition, and now to the brink of a possible cure for a select few.
The Patient’s Dual Diagnosis
In 1999 the Toronto man—who later requested anonymity—was diagnosed with stage 4 Burkitt lymphoma, an aggressive cancer that had already invaded his brain and lymph nodes. Routine testing revealed HIV infection, a grim coincidence given lymphoma’s association with the virus. At that point, physicians expected him to survive less than six months. Dr. Walmsley pursued aggressive treatment for both malignancies, a decision that ultimately set the stage for a later stem‑cell transplant.
Why a Stem‑Cell Transplant?
Antiretroviral therapy (ART) introduced in the late‑1990s suppressed the patient’s HIV to undetectable levels, but stopping ART invariably led to viral rebound within weeks. Researchers understood that HIV hides in long‑lived memory immune cells, forming a reservoir that survives drug pressure. A stem‑cell transplant offers a chance to replace the patient’s immune system with donor cells lacking the CCR5 co‑receptor, the gateway HIV uses to enter cells. Because the patient also needed curative therapy for his leukemia, the transplant served a dual purpose: treat cancer and potentially eradicate HIV.
Finding the Perfect Donor
Dr. Jonas Mattsson, director of the Hans Messner Allogeneic Transplant Program at Toronto’s Princess Margaret Cancer Centre, led the donor search. Using an international registry of over 45 million donors, his team filtered for youth, blood‑type compatibility, and finally screened for the protective CCR5‑Δ32 mutation. Remarkably, they identified three suitable donors—a rare “hit” that Mattsson likened to a hockey team scoring. The search highlighted both the promise and the inequities of stem‑cell matching; Caucasian patients like this one have a higher chance of finding a match because most registered donors are of European ancestry.
The Transplant and Its Perils
In July 2021 the patient underwent conditioning chemotherapy and radiation to wipe out his native immune system, followed by infusion of the donor stem cells. The procedure is inherently hazardous: at Princess Margaret, roughly 31 % of transplant recipients do not survive three years due to cancer relapse or complications. The patient endured multiple infections, a fractured hip, and graft‑versus‑host disease (GVHD), a common but sometimes fatal post‑transplant complication. Notably, GVHD may also contribute to clearing the HIV reservoir, adding a complex layer to the outcome.
Monitoring the Viral Reservoir
Dr. Mario Ostrowski, a clinician‑scientist at St. Michael’s Hospital, performed specialized high‑containment assays to measure any lingering HIV DNA in the patient’s immune cells. Immediately after transplant, HIV levels dropped, but Dr. Walmsley withheld ART cessation until she was confident the reservoir was truly eradicated. In July 2025, four years post‑transplant, a single cell harboring an intact HIV genome was detected, raising concerns about possible rebound. Nonetheless, the patient insisted on stopping ART, motivated by the prospect of contributing to HIV cure research.
Sustained Remission and the Path to Cure
Ten months after discontinuing antiretrovirals, the patient continues to show no detectable HIV in blood or tissue samples. If he remains HIV‑negative for a total of 20 months post‑treatment, he will meet the formal criteria for an HIV cure, joining the exclusive group of ten individuals worldwide cured via stem‑cell transplantation. His prolonged remission has not altered daily life dramatically, but he expresses pride in advancing scientific knowledge that may one day lead to safer, widely applicable cures.
Why Stem‑Cell Transplants Are Not a Global Solution
Both Dr. Walmsley and her collaborators stress that the procedure is unsuitable for the vast majority of the 41 million people living with HIV. It is medically risky, prohibitively expensive—hundreds of thousands of dollars per transplant—and requires sophisticated infrastructure unavailable in many low‑income regions. Moreover, the transplant was undertaken only because the patient needed it for life‑threatening cancer; the HIV cure was a fortunate side effect. Consequently, the approach serves primarily as a proof‑of‑concept rather than a scalable public‑health intervention.
Scientific Hope and Future Directions
Each cured patient offers fresh clues about HIV’s persistence and the immune mechanisms that can eradicate it. The Toronto case underscores the potential role of graft‑versus‑host disease in reducing the viral reservoir and highlights the importance of CCR5‑deficient donor cells. Researchers hope to translate these insights into less invasive strategies—such as gene editing to reproduce CCR5 mutations, immunotherapy to activate latent virus, or therapeutic vaccines—to achieve remission without the dangers of transplantation.
Reflections on Four Decades of HIV Care
Looking back, Dr. Walmsley recalls sitting at patients’ bedsides in the early 1980s, watching them die within months. Today, she sees a trajectory from inevitable death to chronic management and now to the possibility of cure for a few. While she acknowledges that bone‑marrow transplant will never be the answer for most, she views it as an essential stepping stone: “It does provide a pathway to understand what needs to be done in order to try and develop a cure.” Her perspective encapsulates both the triumphs and the enduring challenges in the ongoing fight against HIV.